Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29646414 | 0.79 | ADORA3 (0.69) | ADORA3ADORA1MAPTMEN1KMT2A | |
| SCHEMBL22979023 | 0.79 | ADORA3 (0.69) | ADORA3ADORA1MAPTMEN1KMT2A | |
| SCHEMBL22979092 | 0.79 | ADORA3 (0.45) | ADORA3ADORA1MAPT | |
| SCHEMBL22988249 | 0.77 | NR1H2 (0.32) | ADORA3ADORA1SMN1; SMN2 | |
| SCHEMBL22979760 | 0.77 | ADORA3 (0.46) | ADORA3ADORA1MAPTMEN1KMT2A | |
| SCHEMBL22987585 | 0.75 | ADORA3 (0.44) | ADORA3ADORA1MAPTTHRBPOLB | |
| SCHEMBL22987589 | 0.75 | ADORA3 (0.46) | ADORA3ADORA1MAPTMEN1KMT2A | |
| SCHEMBL22979908 | 0.75 | ADORA3 (0.50) | ADORA3ADORA1MAPTMEN1KMT2A | |
| SCHEMBL22987398 | 0.75 | HPGD (0.51) | ADORA3ADORA1MAPTMEN1KMT2A | |
| SCHEMBL22979578 | 0.75 | ADORA3 (0.64) | ADORA3ADORA1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114466850-B | [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine | 拜耳股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114466850-A | [1,2,4] triazolo [1,5-C ] quinazolin-5-amines | 拜耳股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA3 34/4885ADORA1 21/4885MAPT 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.